Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1693161 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Yutao Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Gastrointestinal Microbiome, Carcinogenesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A substantial body of evidence has elucidated the critical role of gut microbiota in the development and progression of colorectal cancer (CRC). Gut dysbiosis, defined as the disruption of microbiome homeostasis, has been implicated in the pathogenesis of various diseases, including CRC, Parkinson’s disease, and autoimmune liver disorders. In recent years, research has increasingly focused on microbial metabolites, with numerous studies confirming their association with CRC. This review systematically elucidates the dual roles of microbial metabolites in the initiation and progression of CRC: they can suppress tumors by strengthening the gut barrier, reducing inflammation, blocking abnormal cell growth, and triggering apoptosis; yet under dysbiotic conditions-like chronic inflammation or epithelial injury-they may promote cancer by releasing inflammatory cytokines, damaging DNA, and driving uncontrolled proliferation. We summarize key findings on these metabolites’ functions in CRC, highlight emerging metabolite-targeted therapies, and identify major hurdles to clinical translation: metabolite instability, individual variation in host-microbe interactions, and absent biomarkers for patient selection. Because the gut microbiota-metabolite axis is central to CRC biology, targeting it rationally offers a promising path to more precise and effective treatments. Ultimately, gut metabolites are not just disease indicators-they are actionable therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China.
Zitieren
APA
Jin, Y., Zhu, H., Fan, J., & Xu, H. (2026). Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1693161
Vancouver
Jin Y, Zhu H, Fan J, Xu H. Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1693161
BibTeX
@article{Jin2026,
author = {Jin, Yutao and Zhu, He and Fan, Jiawei and Xu, Hong},
title = {Gut microbial metabolites in colorectal cancer: dual roles in tumorigenesis, immune crosstalk, and therapeutic innovation},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1693161}
}
EUVIMED